Shouldn't adults with growth hormone deficiency be offered growth hormone replacement therapy?
Growth hormone as therapy for adults with growth hormone deficiency has not been universally accepted by endocrinologists who treat adult patients. The following are addressed in this commentary: the evidence on safety and efficacy in the literature supporting the idea that growth hormone should be offered as replacement therapy to adults who are growth hormone deficient; common concerns of the average prescribing endocrinologist, including the purported association between insulin-like growth factor-I and malignant neoplasms and quality-of-life issues with long-term therapy; and controversial subjects, such as differences in dosing for adults versus children and diagnostic issues. This analysis should encourage reluctant practitioners to at least consider growth hormone replacement therapy for patients with definite growth hormone deficiency--that is, patients with symptomatic panhypopituitarism.
Cook
David M
DM
Oregon Health and Science University, Portland, Oregon, USA. cookd@ohsu.edu
D000328:Adult; D016903:Drug Monitoring; D011307:Drug Prescriptions; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D019382:Human Growth Hormone / Q000009:adverse effects / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D007018:Hypopituitarism / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D007349:Insurance, Health, Reimbursement; D008297:Male; D010818:Practice Patterns, Physicians'; D012307:Risk Factors; D013577:Syndrome
D019382:Human Growth Hormone